09:45 ET -- Eli Lilly is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Eli Lilly said Tuesday it is paying $48 a share of DICE Therapeutics to buy the smaller biopharmaceutical company for $2.4 billion, which would represent a premium of about 40% to DICE's 30-day volume-weighted average trading price up to its last trading day on Friday. The transaction is expected to close in the third quarter of this year. Dow Jones & Co. owns Factiva. (chris.wack@wsj.com)

 

(END) Dow Jones Newswires

June 20, 2023 10:00 ET (14:00 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
DICE Therapeutics (NASDAQ:DICE)
過去 株価チャート
から 4 2024 まで 5 2024 DICE Therapeuticsのチャートをもっと見るにはこちらをクリック
DICE Therapeutics (NASDAQ:DICE)
過去 株価チャート
から 5 2023 まで 5 2024 DICE Therapeuticsのチャートをもっと見るにはこちらをクリック